Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 5/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | TAS2R8 | Q9NYW2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3734827 | 0.85 | IGF1R (0.54) | SMOIGF1R | |
| Trifluoroacetic Acid SCHEMBL3726606 | 0.85 | IGF1R (0.54) | SMOIGF1R | |
| Trifluoroacetic Acid SCHEMBL2942569 | 0.84 | IGF1R (0.58) | SMOIGF1RTAS2R8F2F10 | |
| Trifluoroacetic Acid SCHEMBL2940273 | 0.84 | IGF1R (0.58) | SMOIGF1RTAS2R8F2F10 | |
| Trifluoroacetic Acid SCHEMBL3727904 | 0.84 | IGF1R (0.58) | SMOIGF1RTAS2R8F2F10 | |
| SCHEMBL2941262 | 0.78 | IGF1R (0.60) | SMOIGF1R | |
| SCHEMBL2940768 | 0.78 | IGF1R (0.60) | SMOIGF1R | |
| SCHEMBL2940771 | 0.78 | IGF1R (0.60) | SMOIGF1R | |
| SCHEMBL2939667 | 0.77 | IGF1R (0.64) | SMOIGF1RTAS2R8ALDH1A1 | |
| SCHEMBL2939674 | 0.77 | IGF1R (0.64) | SMOIGF1RTAS2R8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-01-24 | — | — | US | disclosed |
| EP-1621535-A1 | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | PRKAR2B, PRKG2, PRKG1 | SMO 2832/4885IGF1R 878/4885TAS2R8 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.